Manikomycin reveals a new weakness in drug-resistant bacteria by blocking ribosome exit

TL;DR Summary
McMaster University researchers led by Gerry Wright discovered manikomycin, a novel antibiotic that blocks the ribosome exit site, effectively killing drug-resistant bacteria such as Salmonella, E. coli and Klebsiella and representing a new class of antibiotics; found by fractionating extracts of Streptomyces rimosus, it is non-toxic to human cells in early tests, with 60 derivatives developed and plans to optimize its activity and expand its spectrum.
Topics:health#antibiotic#drugresistance#manikomycin#note-extra-tag-trimmed#ribosomeexitsite#science#streptomycesrimosus
- McMaster researcher’s latest antibiotic discovery offers new way to kill drug-resistant bacteria McMaster News
- New antibiotic kills drug-resistant bacteria by targeting previously unknown vulnerability Medical Xpress
- New synthetic antibiotics could defeat MRSA and prevent relapsing infections The Brighter Side of News
- Natural Depsipeptide Antibiotic Targets Bacterial Ribosome Bioengineer.org
- New Antibiotic, Manikomycin, Acts on Novel Ribosomal Target Genetic Engineering and Biotechnology News
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
4 min
vs 4 min read
Condensed
92%
778 → 66 words
Want the full story? Read the original article
Read on McMaster News